LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.09

  LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards®
  Version 3.09

Business Wire

ALAMEDA, Calif. -- November 19, 2012

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the release of GeneCards^®, Version 3.09, on November 18,
2012. The new release is available at LifeMap Sciences
holds the exclusive worldwide license to market GeneCards^® from Yeda Research
and Development Company Ltd., the commercial arm of the Weizmann Institute of

GeneCards^® is a comprehensive online database that provides concise genomic
information on all known and predicted human genes. The recent GeneCards^®
release greatly enhances the representation of non-protein coding RNA genes
based, among other sources, on the ENCODE Project, an international
collaborative effort to identify all functional elements in the human genome
sequence. With over 12 million page visits per year from hundreds of thousands
of unique users worldwide, GeneCards^® is accessed by professionals in
academia, research hospitals, patent offices, and leading biotech and pharma
companies. GeneCards^® was developed, and is continuously enhanced by ongoing
research, by the bioinformatics team at the Department of Molecular Genetics
at the Weizmann Institute of Science in Israel, with principal investigator
Professor Doron Lancet, head of the Crown Human Genome Center, and team leader
Marilyn Safran.

The new GeneCards^® release includes more than 122,000 gene entries. One of
the important enhancements is the revamped normal tissue gene expression
section, which now shows images for 16 tissues based on RNA-seq data of the
Illumina BodyMap project, as well as a greatly enhanced number of 80 tissues
from BioGPS. Another key enrichment is expression data in an anatomical and
embryonic developmental context, obtained from LifeMap Discovery™, the
database of embryonic development, stem-cell research and regenerative
medicine. Also included are improved functionality for non-coding RNA genes
(multi-source overlap graphics, subcategories, and quality scores)
gene-associated diseases from MalaCards (, pathways from
new sources and new gene-related research reagents.

“The significantly upscaled gene expression and non-coding RNA sectors, as
well as the new strong links to MalaCards and LifeMap Discovery™, are parts of
our long-term research strategy, and bring new discovery strength to
GeneCards^®,” said Professor Doron Lancet, Ph.D., The Ralph D. and Lois R.
Silver Professor of Human Genomics, at the Weizmann Institute of Science.

“Providing anatomical and developmental context, enriching disease related
information, and improving our gene expression data in GeneCards are big steps
forward for our platform,” stated Yaron Guan-Golan, Head of Marketing at
LifeMap Sciences. “We are delighted to see the continued improvement of
GeneCards’ features and content, the establishment of MalaCards, and the
inclusion of novel data from our upcoming LifeMap Discovery^TM database. The
synergies between GeneCards^®, MalaCards and LifeMap Discovery^TM will
significantly enhance basic research, and contribute greatly to the discovery
and development of novel diagnostic and therapeutic products and

About LifeMap Sciences, Inc.

LifeMap Sciences’ ( core technology and business is based on
its integrated database suite, the discovery platform for biomedical and
stem-cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, BioTime plans to make LifeMap Sciences
BioTime’s principal marketing subsidiary for research products, including
PureStem™ human progenitor cell lines, GMP human embryonic stem (hES) cell
lines, ESpan™ growth media for progenitor cell lines, and cell differentiation
media for non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap
Sciences will utilize its databases as part of its online marketing strategy
to reach life sciences researchers at biotech and pharmaceutical companies and
at academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database. LifeMap will
also market BioTime research products. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at

About the Weizmann Institute of Science

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's
top-ranking multidisciplinary research institutions. Noted for its
wide-ranging exploration of the natural and exact sciences, the Institute is
home to 2,700 scientists, students, technicians and supporting staff.
Institute research efforts include the search for new ways of fighting disease
and hunger, examining leading questions in mathematics and computer science,
probing the physics of matter and the universe, creating novel materials and
developing new strategies for protecting the environment.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390 ext. 367
Judith Segall
510-521-3390 ext. 301
LifeMap Sciences, Inc.
Kenneth Elsner
Press spacebar to pause and continue. Press esc to stop.